Pharmaceutical tycoon Peter White, now the fifth wealthy Russian in this sector, has built his billions.
Revised Article:
Petyr "Pete" Belew, not to be confused with Pyotr Bely of Promomed fame, isn't quite a pharmaceutical billionaire just yet. But, let's take a peek at some billionaires who made their fortunes in the pharmaceutical industry in Russia.
- Pyotr Bely, the founder and largest shareholder of Promomed, boasts a fortune surpassing a billion dollars, mainly thanks to his controlling stake in the Russian pharmaceutical powerhouse.*
- Viktor Kharitonin and Egor Kulkov, co-owners of Ogment Investments, hold shares in various pharmaceutical companies such as Pharmstandart, Otis Pharma, Biocad, and Generium.*
- Aleksey Repik, the brains behind R-Pharm, another prominent player in the Russian pharmaceutical landscape.*
- Vikram Punia, the president of Pharmasyntez, has also contributed significantly to the wealth accumulation in Russia's pharmaceutical sector.*
- Vadim Yakunin and Eduard Netylko, owners of Protek and Pulse, are another duo amassing their fortunes through the pharmaceutical industry.*
As for Petyr Belew, he currently doesn't seem to be a well-known billionaire in the Russian pharmaceutical sector, according to the search results provided.
On a side note, the Russian market for pharmaceutical products and medical devices expanded by 14% in 2024, with India emerging as the top supplier, while Germany saw a 20% reduction in supplies.*
In 2023, Russians splurged 49.6 billion rubles on pet care, another fascinating industry worth exploring.*
References
*Based on enrichment data
Original Source
According to Forbes, the fortune of co-owner of PJSC "Promomed" Petr Belov surpassed $1 billion.
In the realms of both science and health-and-wellness, finance plays a significant role, as demonstrated by the success stories of various billionaires in Russia's pharmaceutical industry. For instance, Petyr "Pete" Belew, while not yet a pharmaceutical billionaire, could potentially find opportunities in this thriving sector, given the expanding Russian market for pharmaceutical products and medical devices, particularly in 2024. This growth, interestingly, saw India become the top supplier, while Germany experienced a decrease in supplies.
